Related Experiment Video
Updated: Dec 13, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Neoadjuvant chemotherapy for high-risk prostatic adenocarcinoma
Robert Brunner1, Bradley Buck1, Zane Giffen1
1Department of Urology College of Medicine and Life Sciences The University of Toledo Toledo Ohio USA.
Introduction:
Neoadjuvant chemotherapy in high-risk, locally advanced prostate cancer remains an understudied area of prostate cancer. Chemotherapy continues to be a viable option. The combination with surgery may be desired but lacks data for complete recommendation.
Case Presentation:
We demonstrate the successful utilization of chemotherapy in the neoadjuvant arena. A 70-year-old male was diagnosed with high-risk prostate cancer on biopsy. Upon multiparametric magnetic resonance imaging, the patient had local rectal wall invasion and stage T4 N0 M0 after a negative bone scan. After treatment with androgen-deprivation therapy and docetaxel, repeat multiparametric magnetic resonance imaging showed regression of rectal invasion. The patient elected for prostatectomy and avoided proctectomy and colostomy. The patient's postoperative prostate-specific antigen was undetectable on initial follow-up.
Conclusion:
We show that neoadjuvant chemotherapy merits further study and may provide a more permanent surgical option for patients.
